AI Article Synopsis
- Nirmatrelvir-ritonavir (NMVr) is a treatment for high-risk patients with symptomatic COVID-19, particularly those with cardiovascular issues who face greater risks from the virus.
- Ritonavir enhances NMVr's effectiveness but also inhibits key enzymes (CYP450, especially CYP3A4) and impacts drug transport, leading to potential interactions with cardiovascular medications.
- The review highlights the importance of understanding and managing these drug-drug interactions to prevent severe adverse effects in patients receiving NMVr along with other cardiovascular treatments.
Article Abstract
Nirmatrelvir-ritonavir (NMVr) is used to treat symptomatic, nonhospitalized patients with coronavirus disease-2019 (COVID-19) who are at high risk of progression to severe disease. Patients with cardiovascular risk factors and cardiovascular disease are at a high risk of developing adverse events from COVID-19 and as a result have a higher likelihood of receiving NMVr. Ritonavir, the pharmaceutical enhancer used in NMVr, is an inhibitor of the enzymes of CYP450 pathway, particularly CYP3A4 and to a lesser degree CYP2D6, and affects the P-glycoprotein pump. Co-administration of NMVr with medications commonly used to manage cardiovascular conditions can potentially cause significant drug-drug interactions and may lead to severe adverse effects. It is crucial to be aware of such interactions and take appropriate measures to avoid them. In this review, we discuss potential drug-drug interactions between NMVr and commonly used cardiovascular medications based on their pharmacokinetics and pharmacodynamic properties.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9580069 | PMC |
| http://dx.doi.org/10.1016/j.jacc.2022.08.800 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!